Literature DB >> 12839936

Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer.

Sharad Khare1, Sonia Cerda, Ramesh K Wali, Friederike C von Lintig, Maria Tretiakova, Loren Joseph, Debra Stoiber, Greg Cohen, Kiran Nimmagadda, John Hart, Michael D Sitrin, Gerry R Boss, Marc Bissonnette.   

Abstract

K-ras mutations occur frequently in colon cancer and contribute to autonomous growth. In the azoxymethane (AOM) model of colon cancer, in addition to K-ras mutations, we have shown that wild-type (WT) Ras can be activated by upstream pathways, including, e.g., signaling by ErbB receptors. Tumors with mutant or activated WT Ras had increased cyclooxygenase-2 (Cox-2) expression. We have also shown that ursodeoxycholic acid (UDCA) prevented AOM-induced colon cancer and suppressed Cox-2 induction. In this study, we examined the role of Ras in Cox-2 inhibition by UDCA. Rats were fed AIN-76A chow alone, or supplemented with 0.4% UDCA, and received 20 mg/kg AOM i.p. weekly x 2 weeks. At 40 weeks, rats were sacrificed, and tumors were harvested. K-ras mutations were assessed by primer-mediated RFLP, allele-specific oligonucleotide hybridization, and direct DNA sequencing. Ras was immunoprecipitated and defined as activated if [Ras - GTP/(Ras - GTP + Ras - GDP)] was >3 SD above normal colonocytes. Cox-2 mRNA was determined by reverse transcription-PCR, and protein expression was assessed by Western blotting and immunostaining. In the AOM alone group, Ras was activated by mutations in 8 of 30 (27%) tumors, and WT Ras was activated in 7 of 30 (23%) tumors. UDCA significantly suppressed the incidence of tumors with mutant Ras (1 of 31, 3.2%; P < 0.05) and totally abolished the development of tumors with activated WT Ras (0 of 10; P < 0.05). In the AOM alone group, Cox-2 was up-regulated >50-fold in tumors with normal Ras activity and further enhanced in tumors with mutant or signaling-activated Ras. UDCA significantly inhibited Cox-2 protein and mRNA levels in tumors with normal Ras activity. In summary, we have shown for the first time that UDCA suppressed the development of tumors with Ras mutations and blocked activation of WT Ras. Furthermore, UDCA inhibited Cox-2 induction by Ras-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839936

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

Authors:  G Rudolph; D N Gotthardt; P Kloeters-Plachky; H Kulaksiz; P Schirmacher; A Stiehl
Journal:  Dig Dis Sci       Date:  2011-06-09       Impact factor: 3.199

2.  Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.

Authors:  Jamie M Golden; Oswaldo H Escobar; Michelle V L Nguyen; Michael U Mallicote; Patil Kavarian; Mark R Frey; Christopher P Gayer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-04-19       Impact factor: 4.052

3.  Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.

Authors:  Darcey L H Smith; Pavitra Keshavan; Uri Avissar; Kashif Ahmed; Stephen D Zucker
Journal:  Carcinogenesis       Date:  2010-03-01       Impact factor: 4.944

4.  Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.

Authors:  Alessandro Fichera; Nathaniel Little; Sujatha Jagadeeswaran; Urszula Dougherty; Amikar Sehdev; Reba Mustafi; Sonia Cerda; Weihua Yuan; Sharad Khare; Maria Tretiakova; Can Gong; Michael Tallerico; Greg Cohen; Loren Joseph; John Hart; Jerrold R Turner; Marc Bissonnette
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

Review 5.  Intestinal bile acid physiology and pathophysiology.

Authors:  Olga Martinez-Augustin; Fermin Sanchez de Medina
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

6.  Clostridium scindens baiCD and baiH genes encode stereo-specific 7alpha/7beta-hydroxy-3-oxo-delta4-cholenoic acid oxidoreductases.

Authors:  Dae-Joong Kang; Jason M Ridlon; Doyle Ray Moore; Stephen Barnes; Phillip B Hylemon
Journal:  Biochim Biophys Acta       Date:  2007-11-07

Review 7.  Exploring the Role of Gut Microbiome in Colon Cancer.

Authors:  Indranil Chattopadhyay; Ruby Dhar; Karthikeyan Pethusamy; Ashikh Seethy; Tryambak Srivastava; Ramkishor Sah; Jyoti Sharma; Subhradip Karmakar
Journal:  Appl Biochem Biotechnol       Date:  2021-01-25       Impact factor: 2.926

8.  Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas.

Authors:  C Holgren; U Dougherty; F Edwin; D Cerasi; I Taylor; A Fichera; L Joseph; M Bissonnette; S Khare
Journal:  Oncogene       Date:  2010-07-26       Impact factor: 9.867

9.  The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.

Authors:  Wen-Kuan Huang; Hung-Chih Hsu; Jia-Rou Liu; Tsai-Sheng Yang; Jen-Shi Chen; John Wen-Cheng Chang; Yung-Chang Lin; Kuang-Hui Yu; Chang-Fu Kuo; Lai-Chu See
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 10.  Dysbiosis of gut microbiota in promoting the development of colorectal cancer.

Authors:  Shaomin Zou; Lekun Fang; Mong-Hong Lee
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.